Skip to main content
Erschienen in: Endocrine 1/2015

01.02.2015 | Original Article

Uric acid induces oxidative stress via an activation of the renin–angiotensin system in 3T3-L1 adipocytes

verfasst von: Jun-xia Zhang, Yu-ping Zhang, Qi-nan Wu, Bing Chen

Erschienen in: Endocrine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Hyperuricemia is recently reported involving in various obesity-related cardiovascular disorders, especially hypertension. However, the underlying mechanisms are not completely understood. In the present study, we investigated whether uric acid upregulates renin–angiotensin system (RAS) expression in adipocytes. We also examined whether RAS activation plays a role in uric acid-induced oxidative stress in adipocytes. The adipocytes of different phenotypes were incubated with uric acid for 48 h, respectively. Losartan (10−4 M) or captopril (10−4 M) was used to block adipose tissue RAS activation. mRNA expressions of angiotensinogen (AGT), angiotensin-converting enzyme-1 (ACE-1), renin, angiotensin type 1 receptor (AT1R), and angiotensin type 2 receptor (AT2R) were evaluated with real-time PCR. Angiotensin II concentrations in supernatant were measured by ELISA. Intracellular reactive species (ROS) levels were measured by fluorescent probe DCFH-DA, DHR, or NBT assay. The uric acid upregulated both RAS (AGT, ACE1, renin, AT1R, and AT2R) mRNA expressions and angiotensin II protein secretion and caused a significant increase in ROS production in 3T3-L1 adipocytes. These effects could be prevented by RAS inhibitors, either losartan or captopril. RAS activation has been causally implicated in oxidative stress induced by uric acid in 3T3-L1 adipocytes, suggesting a plausible mechanism through which hyperuricemia contributes to the pathogenesis of obesity-related cardiovascular diseases.
Literatur
2.
Zurück zum Zitat I. Saito, T. Saruta, K. Kondo, R. Nakamura, T. Oguro, K. Yamagami, Y. Ozawa, E. Kato, Serum uric acid and the renin–angiotensin system in hypertension. J. Am. Geriatr. Soc. 26, 241–247 (1978)PubMed I. Saito, T. Saruta, K. Kondo, R. Nakamura, T. Oguro, K. Yamagami, Y. Ozawa, E. Kato, Serum uric acid and the renin–angiotensin system in hypertension. J. Am. Geriatr. Soc. 26, 241–247 (1978)PubMed
3.
Zurück zum Zitat D.I. Feig, B. Soletsky, R.J. Johnson, Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924–932 (2008)CrossRefPubMedCentralPubMed D.I. Feig, B. Soletsky, R.J. Johnson, Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924–932 (2008)CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat W. Susumu, K. Duk-Hee, F. Lili, N. Takahiko, K. John, L. Hui, Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40, 355–360 (2002)CrossRef W. Susumu, K. Duk-Hee, F. Lili, N. Takahiko, K. John, L. Hui, Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40, 355–360 (2002)CrossRef
5.
Zurück zum Zitat M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.Y. Xia, Q. Chen, Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal. Physiol. 282, F991–997 (2002)PubMed M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.Y. Xia, Q. Chen, Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal. Physiol. 282, F991–997 (2002)PubMed
6.
Zurück zum Zitat D.B. Corry, P. Eslami, K. Yamamoto, M.D. Nyby, H. Makino, M.L. Tuck, Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J. Hypertens. 26, 269–275 (2008)CrossRefPubMed D.B. Corry, P. Eslami, K. Yamamoto, M.D. Nyby, H. Makino, M.L. Tuck, Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J. Hypertens. 26, 269–275 (2008)CrossRefPubMed
7.
Zurück zum Zitat M.A. Yu, L.G. Sánchez-Lozada, R.J. Johnson, D.H. Kang, Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 28, 1234–1242 (2010)PubMed M.A. Yu, L.G. Sánchez-Lozada, R.J. Johnson, D.H. Kang, Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 28, 1234–1242 (2010)PubMed
8.
Zurück zum Zitat G. Albertoni, E. Maquigussa, E. Pessoa, J.A. Barreto, F. Borges, N. Schor, Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 235, 825–832 (2010)CrossRef G. Albertoni, E. Maquigussa, E. Pessoa, J.A. Barreto, F. Borges, N. Schor, Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 235, 825–832 (2010)CrossRef
9.
Zurück zum Zitat N.S. Kalupahana, N. Moustaid-Moussa, The renin–angiotensin system: a link between obesity, inflammation and insulin resistance. Obes. Rev. 13, 136–149 (2012)CrossRefPubMed N.S. Kalupahana, N. Moustaid-Moussa, The renin–angiotensin system: a link between obesity, inflammation and insulin resistance. Obes. Rev. 13, 136–149 (2012)CrossRefPubMed
10.
Zurück zum Zitat S. Thatcher, F. Yiannikouris, M. Gupte, L. Cassis, The adipose renin–angiotensin system: role in cardiovascular disease. Mol. Cell. Endocrinol. 302, 111–117 (2009)CrossRefPubMedCentralPubMed S. Thatcher, F. Yiannikouris, M. Gupte, L. Cassis, The adipose renin–angiotensin system: role in cardiovascular disease. Mol. Cell. Endocrinol. 302, 111–117 (2009)CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Y.Y. Sautin, T. Nakagawa, S. Zharikov, R.J. Johnson, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am. J. Physiol. Cell Physiol. 293, C584–596 (2007)CrossRefPubMed Y.Y. Sautin, T. Nakagawa, S. Zharikov, R.J. Johnson, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am. J. Physiol. Cell Physiol. 293, C584–596 (2007)CrossRefPubMed
12.
Zurück zum Zitat A. Kurata, H. Nishizawa, S. Kihara, N. Maeda, M. Sonoda, T. Okada, K. Ohashi, T. Hibuse, K. Fujita, A. Yasui, A. Hiuge, M. Kumada, H. Kuriyama, I. Shimomura, T. Funahashi, Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 70, 1717–1724 (2006)CrossRefPubMed A. Kurata, H. Nishizawa, S. Kihara, N. Maeda, M. Sonoda, T. Okada, K. Ohashi, T. Hibuse, K. Fujita, A. Yasui, A. Hiuge, M. Kumada, H. Kuriyama, I. Shimomura, T. Funahashi, Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 70, 1717–1724 (2006)CrossRefPubMed
13.
Zurück zum Zitat S.C. Frost, M.D. Lane, Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J. Biol. Chem. 260, 2646–2652 (1985)PubMed S.C. Frost, M.D. Lane, Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J. Biol. Chem. 260, 2646–2652 (1985)PubMed
14.
Zurück zum Zitat M. Fujimoto, H. Masuzaki, T. Tanaka, S. Yasue, T. Tomita, K. Okazawa, An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 (2004)CrossRefPubMed M. Fujimoto, H. Masuzaki, T. Tanaka, S. Yasue, T. Tomita, K. Okazawa, An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 (2004)CrossRefPubMed
15.
Zurück zum Zitat J. Kanellis, S. Watanabe, J.H. Li, D.H. Kang, P. Li, T. Nakagawa, Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287–1293 (2003)CrossRefPubMed J. Kanellis, S. Watanabe, J.H. Li, D.H. Kang, P. Li, T. Nakagawa, Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287–1293 (2003)CrossRefPubMed
16.
Zurück zum Zitat K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, R.W. Alexander, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141–1148 (1994)CrossRefPubMed K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, R.W. Alexander, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141–1148 (1994)CrossRefPubMed
17.
Zurück zum Zitat B.H. Jones, M.K. Standridge, J.W. Taylor, N. Moustaid, Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 273, R236–242 (1997)PubMed B.H. Jones, M.K. Standridge, J.W. Taylor, N. Moustaid, Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 273, R236–242 (1997)PubMed
18.
Zurück zum Zitat C. Karlsson, K. Lindell, M. Ottosson, L. Sjostrom, B. Carlsson, L.M. Carlsson, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83, 3925–3929 (1998)PubMed C. Karlsson, K. Lindell, M. Ottosson, L. Sjostrom, B. Carlsson, L.M. Carlsson, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83, 3925–3929 (1998)PubMed
19.
Zurück zum Zitat F. Massiéra, M. Bloch-Faure, D. Ceiler, K. Murakami, A. Fukamizu, J.M. Gasc, A. Quignard-Boulange, R. Negrel, G. Ailhaud, J. Seydoux, P. Meneton, M. Teboul, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15, 2727–2729 (2001)PubMed F. Massiéra, M. Bloch-Faure, D. Ceiler, K. Murakami, A. Fukamizu, J.M. Gasc, A. Quignard-Boulange, R. Negrel, G. Ailhaud, J. Seydoux, P. Meneton, M. Teboul, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15, 2727–2729 (2001)PubMed
20.
Zurück zum Zitat S. Kim, M. Soltani-Bejnood, A. Quignard-Boulange, F. Massiera, M. Teboul, G. Ailhaud, J.H. Kim, N. Moustaid-Moussa, B.H. Voy, The adipose renin–angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin–angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006)CrossRefPubMedCentralPubMed S. Kim, M. Soltani-Bejnood, A. Quignard-Boulange, F. Massiera, M. Teboul, G. Ailhaud, J.H. Kim, N. Moustaid-Moussa, B.H. Voy, The adipose renin–angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin–angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006)CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat G.K. Glantzounis, E.C. Tsimoyiannis, A.M. Kappas, D.A. Galaris, Uric acid and oxidative stress. Curr. Pharm. Des. 11, 4145–4151 (2005)CrossRefPubMed G.K. Glantzounis, E.C. Tsimoyiannis, A.M. Kappas, D.A. Galaris, Uric acid and oxidative stress. Curr. Pharm. Des. 11, 4145–4151 (2005)CrossRefPubMed
22.
Zurück zum Zitat R. Stocker, J. Keaney Jr, Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed R. Stocker, J. Keaney Jr, Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed
23.
Zurück zum Zitat R.J. Johnson, D.H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K.R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta, M. Mazzali, Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183–1190 (2003)CrossRefPubMed R.J. Johnson, D.H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K.R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta, M. Mazzali, Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183–1190 (2003)CrossRefPubMed
24.
Zurück zum Zitat E. Bonora, G. Targher, M.B. Zenere, F. Saggiani, V. Cacciatori, F. Tosi, D. Travia, M.G. Zenti, P. Branzi, L. Santi, M. Muggeo, Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The verona young men atherosclerosis risk factors study. Int. J. Obes. Relat. Metab. Disord. 20, 975–980 (1996)PubMed E. Bonora, G. Targher, M.B. Zenere, F. Saggiani, V. Cacciatori, F. Tosi, D. Travia, M.G. Zenti, P. Branzi, L. Santi, M. Muggeo, Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The verona young men atherosclerosis risk factors study. Int. J. Obes. Relat. Metab. Disord. 20, 975–980 (1996)PubMed
25.
Zurück zum Zitat T. Ogura, K. Matsuura, Y. Matsumoto, Y. Mimura, M. Kishida, F. Otsuka, K. Tobe, Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism 53, 448–453 (2004)CrossRefPubMed T. Ogura, K. Matsuura, Y. Matsumoto, Y. Mimura, M. Kishida, F. Otsuka, K. Tobe, Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism 53, 448–453 (2004)CrossRefPubMed
26.
Zurück zum Zitat S. Muraoka, T. Miura, Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 93, 284–289 (2003)CrossRefPubMed S. Muraoka, T. Miura, Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 93, 284–289 (2003)CrossRefPubMed
27.
Zurück zum Zitat M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, K.L. Gordon, H.Y. Lan, S. Kivlighn, R.J. Johnson, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101–1106 (2001)CrossRefPubMed M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, K.L. Gordon, H.Y. Lan, S. Kivlighn, R.J. Johnson, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101–1106 (2001)CrossRefPubMed
28.
Zurück zum Zitat L.G. Sánchez-Lozada, V. Soto, E. Tapia, C. Avila-Casado, Y.Y. Sautin, T. Nakagawa, M. Franco, B. Rodríguez-Iturbe, R.J. Johnson, Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am. J. Physiol. Renal. Physiol. 295, F1134–1141 (2008)CrossRefPubMedCentralPubMed L.G. Sánchez-Lozada, V. Soto, E. Tapia, C. Avila-Casado, Y.Y. Sautin, T. Nakagawa, M. Franco, B. Rodríguez-Iturbe, R.J. Johnson, Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am. J. Physiol. Renal. Physiol. 295, F1134–1141 (2008)CrossRefPubMedCentralPubMed
29.
Zurück zum Zitat R.M. Touyz, X. Chen, F. Tabet, G. Yao, G. He, M.T. Quinn, P.J. Pagano, E.L. Schiffrin, Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90, 1205–1213 (2002)CrossRefPubMed R.M. Touyz, X. Chen, F. Tabet, G. Yao, G. He, M.T. Quinn, P.J. Pagano, E.L. Schiffrin, Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90, 1205–1213 (2002)CrossRefPubMed
30.
Zurück zum Zitat R.J. Johnson, D.I. Feig, J. Herrera-Acosta, D.H. Kang, Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45, 18–20 (2005)CrossRefPubMed R.J. Johnson, D.I. Feig, J. Herrera-Acosta, D.H. Kang, Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45, 18–20 (2005)CrossRefPubMed
31.
Zurück zum Zitat K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, M.L. Tuck, Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474–480 (2003)CrossRefPubMed K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, M.L. Tuck, Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474–480 (2003)CrossRefPubMed
32.
Zurück zum Zitat S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004)CrossRefPubMedCentralPubMed S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004)CrossRefPubMedCentralPubMed
Metadaten
Titel
Uric acid induces oxidative stress via an activation of the renin–angiotensin system in 3T3-L1 adipocytes
verfasst von
Jun-xia Zhang
Yu-ping Zhang
Qi-nan Wu
Bing Chen
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0239-5

Weitere Artikel der Ausgabe 1/2015

Endocrine 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.